beta Arrestin 1 CRISPR Activation Plasmid (h): sc-400642-ACT

ARRB1 encodes beta Arrestin 1, a multifunctional adaptor that regulates G protein–coupled receptor (GPCR) desensitization, receptor internalization, and trafficking following agonist stimulation. Beyond terminating G protein signaling, beta Arrestin 1 scaffolds signaling complexes that modulate MAPK/ERK, PI3K–AKT, and NF-κB pathway outputs, shaping context-dependent transcriptional responses and cytoskeletal dynamics. Through these roles, ARRB1 influences processes including chemotaxis, endocytosis, and signal integration downstream of diverse receptors. Dysregulated arrestin-mediated signaling has been associated with altered proliferative and inflammatory signaling states implicated in cancer biology, cardiometabolic regulation, and neuropsychiatric-relevant GPCR circuits.

beta Arrestin 1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous ARRB1 expression without altering the underlying DNA sequence.

beta Arrestin 1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the ARRB1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the ARRB1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous beta Arrestin 1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native ARRB1 locus and enabling the study of beta Arrestin 1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of beta Arrestin 1 pathway restoration in tumor cells with silenced or reduced ARRB1 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.